GemPharmatech (SH:688046) Xin Lang Cai Jing·2025-09-02 01:58Core Insights - Jiangsu Jicui Pharmaceutical Technology Co., Ltd. (药康生物) has shown a mixed performance in its financial metrics, with a revenue increase but a decline in net profit [2][3] - The company has a significant presence in the market for laboratory mouse models, with a diverse revenue stream from various business segments [1] Financial Performance - For the first half of 2025, the company reported a revenue of 375 million yuan, representing a year-on-year growth of 10.11% [2] - The net profit attributable to shareholders was approximately 70.91 million yuan, reflecting a year-on-year decrease of 7.12% [2] Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 23.68% to 7,213, with an average of 56,841 circulating shares per shareholder, up by 62.56% [2] - On September 1, 2023, the company's stock price increased by 1.31%, with a trading volume of approximately 59.66 million yuan [1] Financing and Margin Trading - On September 1, 2023, the company had a net financing outflow of 1.61 million yuan, with a total financing balance of 112 million yuan, accounting for 1.54% of its market capitalization [1] - The margin trading data indicates a high financing balance, while the short selling activity remains relatively low, with a short selling balance of 196,300 yuan [1] Dividend Distribution - Since its A-share listing, the company has distributed a total of 139 million yuan in dividends [3] Institutional Holdings - As of June 30, 2025, notable institutional shareholders include China Europe Medical Health Mixed Fund and others, with some institutions reducing their holdings [3]